Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits

por Ogundele, Abayomi B, Jasek, Mark C
Publicado 2010

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits

por Sheppard, John D., Cockrum, Paul C., Justice, Angela, Jasek, Mark C.
Publicado 2018

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challe...

por Meier, Edward J, Torkildsen, Gail L, Gomes, Paul J, Jasek, Mark C
Publicado 2018

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects

por Malhotra, Ranjan P, Meier, Edward, Torkildsen, Gail, Gomes, Paul J, Jasek, Mark C
Publicado 2019

Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension

por Schnober, Dietmar, Hofmann, Günter, Maier, Hubert, Scherzer, Maria-Luise, Ogundele, Abayomi B, Jasek, Mark C
Publicado 2010

Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy

por Pfeiffer, Norbert, Scherzer, Maria-Luise, Maier, Hubert, Schoelzel, Sonja, Jasek, Mark C, Stewart, Jeanette A, Stewart, William C
Publicado 2010